Business
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with MCT as it most closely represents the setting of a human clinical trial.Human preclinical methods are different as they use a small number of models with a large number of tests per subject. Mouse clinical trials tend to upend the traditional preclinical paradigm and better resemble and match the actual clinical setting. The Company believes this is an effective and cost-efficient way of moving forward. Utilizing MCTs will develop data that can be leveraged for biomarker discovery, which is ever more crucial for clinical trial success.In addition, the Company continues to develop its business model to support the currently licensed IP and providing them with the necessary tools each individual licensor needs to support their individual business so they can contribute to the business plan of Oncology Pharma, Inc.ABOUT ONCOLOGY PHARMA, INC.ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.FORWARD LOOKING STATEMENTSCertain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flo...